Cargando…

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial

Somapacitan is a long-acting, reversible albumin-binding human growth hormone (GH) derivative based on a proven protraction technology. The objective of this trial was to evaluate the safety, efficacy and treatment satisfaction of once-weekly somapacitan compared with daily GH (Norditropin®) over 52...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otsuka, Fumio, Takahashi, Yutaka, Tahara, Shigeyuki, Rasmussen, Michael Højby, Ogawa, Yoshihisa, Takano, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209108/ http://dx.doi.org/10.1210/jendso/bvaa046.605

Ejemplares similares

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

THU073 Somapacitan Administered Subcutaneously At 5 mg/1.5 mL Or 10 mg/1.5 mL Strengths Yields Clinically Similar PK And IGF-I Profiles In Healthy Participants
por: Rasmussen, Michael Højby, et al.
Publicado: (2023)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

MON-473 Growth Hormone (GH) Impacts the Gut Microbial Profile: the Presence of Unique Bacterial Genera in Mouse Lines with Altered GH Action
por: Jensen, Elizabeth, et al.
Publicado: (2019)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

A Case With Adult GH Deficiency Complicated With Osteogenesis Imperfecta: Effect of GH Replacement on Bone Mineral Density
por: Taguchi, Tomomi, et al.
Publicado: (2021)

MON-437 Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to GHRH Receptor Gene Mutation
por: Oliveira-Santos, Alecia, et al.
Publicado: (2019)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

MON-307 Prospective, Longitudinal Study of Glucose-Suppressed GH Levels in 87 Acromegaly Patients with IGF-1 Normalization After Surgical Therapy: Prognostic Value of Nadir GH Levels for Long-Term Remission or Recurrence
por: Freda, Pamela, et al.
Publicado: (2020)

GH Is a Component of SASP in Aging Tissue
por: Chesnokova, Vera M, et al.
Publicado: (2021)

MON-272 Clinical Relevance of Serum Prolactin Levels to Inflammatory Reaction in Male Patients
por: Yamamoto, Koichiro, et al.
Publicado: (2020)

SAT-255 Pituitary Adenoma With TSH and GH Co Secretion
por: Riquelme, Romina, et al.
Publicado: (2020)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019)

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023)

OR16-06 Age-Associated Local GH Promotes Colon Neoplasia
por: Chesnokova, Vera M, et al.
Publicado: (2020)

TSH, GH, and Prolactin Producing Pituitary Adenoma: An Unusual Case Presentation
por: Manrique, Helard Andres, et al.
Publicado: (2021)

PMON129 Pituitary Adenoma Co-Secreting GH, Prolactin and ACTH
por: Wilson, Sarah, et al.
Publicado: (2022)

MON-484 Adipocyte-Specific GH Receptor Knockout Mice (AdGHRKO) Have Enhanced Insulin Sensitivity with Reduced Liver Triglycerides and Depot Specific Analyses in These Mice Suggest that GH May Have a More Substantial Effect on Subcutaneous White Adipose Tissue (WAT) Than Other WAT Depots
por: List, Edward, et al.
Publicado: (2019)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Surgical Remission of Acromegaly Resolves Neuroglycopenia and Paradoxical Rise in GH after OGTT
por: Magar, Maria, et al.
Publicado: (2021)

GH Receptor Exon 3 Genotype and Echocardiographic Abnormalities in Patients With Active Acromegaly
por: Serrano, Karla, et al.
Publicado: (2021)

THU051 GH Resistance And Adipose Tissue: Multispecies Measurement Of Morphology And Transcriptome
por: Young, Jonathan A, et al.
Publicado: (2023)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

Growth Hormone (GH) and Thyroid Stimulating Hormone (TSH) Co-Secreting Pituitary Macroadenoma
por: Maliakal, Alvin, et al.
Publicado: (2021)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

MON-285 Clinical Characteristics of Six Patients with Infundibulo-Neurohypophysitis
por: Nao, Keiko, et al.
Publicado: (2020)

SAT-440 Modulating Effects of Progesterone on Spontaneous and Ghrelin-Induced GH Secretion in Postmenopausal Women
por: Roelfsema, Ferdinand, et al.
Publicado: (2019)

GH1 C.291 + 34G>C in a Growth Hormone Deficient Pedigree
por: Vidal, Katherine, et al.
Publicado: (2021)

THU045 WIP1 Phosphatase Is A Novel Specific Target For Epithelial GH Action
por: Apaydin, Tugce, et al.
Publicado: (2023)

MON-470 Pharmacological Inhibition of LAT1 Suppresses Proliferation and Hormone Synthesis in Rat Pituitary Tumor GH4 Cells [cc1] Synthesis May Be Better as Only mRNAs Were Measured
por: Sato, Motoyasu, et al.
Publicado: (2019)

THU047 Growth Hormone (GH) Signaling In Hepatocytes Controls Hepatic Insulin Sensitivity And Nutrient Disposition
por: del Rio-Moreno, Mercedes, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dqq9etqa6k5vb59qc4kluo8ro8